RESUMO
Objective: To reveal the association between of rs8191670 polymorphism (T/C) of Nei endonuclease VIII-like 2 (Neil2) gene and the sensitivity of non-small cell lung cancer (NSCLC) to cisplatin. Methods: The pathological data of 206 patients with advanced NSCLC diagnosed in the First Affiiated Hospital of Zhengzhou University from May 2011 to January 201 7 were retrospectively reviewed. The mutation of 3'-untranslated region (3'-UTR) of Neil2 gene in peripheral blood of NSCLC patients was detected by RT-PCR and DNA sequencing. Kaplan-Meier method was used for survival analysis. The associations of the polymorphism of rs8191670 in Neil2 gene with the sensitivity and security of platinum-based chemotherapy were evaluated by the log-rank test. Results: T/C polymorphism was found in the rs8191670 locus of Neil2 gene. Among 206 NSCLC patients, there were 1 10 "T/T" homozygote cases, 42 "C/C" homozygote cases and 54 "T/C" heterozygote cases. After cisplatin-based chemotherapy, the median progression-free survival (mPFS) time of NSCLC patients bearing "T/T" homozygote in Neil2 gene rs8191670 locus was better than that of the "C/C" heterozygous patients (6.1 months vs 4.5 months, P 0.05). Conclusion: The rs8191670 polymorphism (T/C) of Neil2 gene changes the repair ability of DNA may through regulating the expression of Neil2 protein, thus affecting the efficacy of cisplatin chemotherapy.